相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection
Karyn M. Sullivan et al.
ANNALS OF PHARMACOTHERAPY (2010)
Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection
Mark Miller
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance
Dhara Shah et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections
Ian R. Poxton
FUTURE MICROBIOLOGY (2010)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
Stuart H. Cohen et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Treatment of Refractory/Recurrent C-difficile-associated Disease by Donated Stool Transplanted Via Colonoscopy A Case Series of 12 Patients
Sonia S. Yoon et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2010)
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
Gerald W. Tannock et al.
MICROBIOLOGY-SGM (2010)
OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C-difficile Infection
Thomas J. Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
High Frequency of Rifampin Resistance Identified in an Epidemic Clostridium difficile Clone from a Large Teaching Hospital
Scott R. Curry et al.
CLINICAL INFECTIOUS DISEASES (2009)
European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)
M. P. Bauer et al.
CLINICAL MICROBIOLOGY AND INFECTION (2009)
Clostridium difficile: controversies and approaches to management
Martijn P. Bauer et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2009)
Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model
Simon D. Baines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Stuart Johnson
JOURNAL OF INFECTION (2009)
Rifampin and rifaximin resistance in clinical isolates of Clostfdium diicile
Jennifer R. O'Connor et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
Wafa N. Al-Nassir et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea
Ju Young Chang et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004
David W. Hecht et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model
Jane Freeman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada
J Pépin et al.
CLINICAL INFECTIOUS DISEASES (2006)
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada
J Pépin et al.
CLINICAL INFECTIOUS DISEASES (2005)
Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube
J Aas et al.
CLINICAL INFECTIOUS DISEASES (2003)
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
L Kyne et al.
LANCET (2001)
分享论文
